DanCann Pharma was founded in 2018 and is a Danish pharmaceutical company. DanCann Pharma focuses on discovering, developing, manufacturing, and commercializing cannabinoid therapeutics in a broad range of disease areas. The company makes prescription (Rx-pharmaceuticals) and over-the-counter (OTC) pharmaceuticals mainly focused on pain patients with alternative needs and management to handle their illness, covered by the Danish Pilot Programme for medical cannabis.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| JEQ Capital AB | 10,42 | 10,42 | 2024-11-25 |
| Niklas Estensson | 4,20 | 4,20 | 2024-11-25 |
| Robert Burén | 4,20 | 4,20 | 2024-11-25 |
| Alexander Schoeneck | 3,83 | 3,83 | 2024-11-25 |
| Erik Lundin | 3,15 | 3,15 | 2024-11-25 |
| Johan Alexander Kangas | 2,52 | 2,52 | 2024-11-25 |
| Nils Berg | 2,52 | 2,52 | 2024-11-25 |
| Love Carlsson | 2,52 | 2,52 | 2024-11-25 |
| Andreas Poike | 2,10 | 2,10 | 2024-11-25 |
| Jonas Hagberg med bolag | 2,10 | 2,10 | 2024-11-25 |
